CTRI/2017/11/010716进行中（未招募）2 期
A Randomized Placebo Controlled Prospective Phase II Clinical Study of an Ayurvedic coded drug AYUSH D on Glycemic Control in Prediabetic Subjects - RAPD
Incharge0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Subjects of either sex, 18-60 years
- •2.Pre-diabetic subjects with HbA1c of 5.7-6.4%.
- •3.Subjects who agree to participate in the study and submit a written informed consent form
排除标准
- •1.Known Cases of DM, both type I and II.
- •2.Past history of gestational diabetes
- •3.Subjects on β-blockers, thiazide diuretics, corticosteroids, HRT.
- •4.Uncontrolled Hypertensive subjects(with or without medication > 140/90 mmHg)
- •5.Any unstable Heart disease
- •6.Patients with concurrent Hepatic Dysfunction (defined as AST and/or ALT > 2 times of the upper normal limit) or Renal Dysfunction (defined as S. creatinine > greater than ULL),uncontrolled Pulmonary Dysfunction (asthmatic and COPD subjects) .
- •7.Pregnant / Lactating women.
- •8.Alcoholics and/or drug abusers
- •9.Patients with evidence of malignancy
- •10.Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Psycho-Neuroendocrinal disorders, etc.)
- •11.Patients who have completed participation in any other clinical trial during the past six (06) months.
- •12.Any other condition which the Investigator thinks may jeopardize the study.
研究者
相似试验
尚未招募
4 期
A study of a food supplement to reverse feeling of tiredness after a viral infectioCTRI/2023/08/056433Carmel Research Consultancy Private Limited
进行中（未招募）
1 期
A Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosison-alcoholic Steatohepatitis (NASH) CirrhosisMedDRA version: 20.0Level: LLTClassification code: 10009214Term: Cirrhosis of liver without mention of alcohol Class: 10019805CTIS2024-510627-20-00Madrigal Pharmaceuticals Inc.700
进行中（未招募）
1 期
A Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosison-alcoholic Steatohepatitis (NASH) CirrhosisMedDRA version: 20.0Level: LLTClassification code 10009214Term: Cirrhosis of liver without mention of alcoholSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2022-002279-13-DEMadrigal Pharmaceuticals, Inc.700
进行中（未招募）
1 期
A Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH CirrhosisEUCTR2022-002279-13-FRMadrigal Pharmaceuticals, Inc.700
已完成
不适用
A Phase 1, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses Oral Doses of APX001, to Investigate the Effect of Food on APX001 and to Investigate the Drug-Drug Interaction Potential of APX001Fungal infectionNL-OMON45345Amplyx Pharmaceuticals, Inc.46